A Wall Street analyst has provided a review for the Healthcare company today, but retained the same rating on the stock. Analyst David Novak from Raymond James rated Biosyent (RX – Research Report) a Buy, setting a C$10 price target.
Novak has an average return of 3.9% when recommending Biosyent.
According to TipRanks.com, Novak is ranked #1355 out of 5181 analysts.
Biosyent has an analyst consensus of Moderate Buy, with a price target consensus of C$10.
The company has a one-year high of C$10.26 and a one-year low of C$6.52. Currently, Biosyent has an average volume of 12.75K.
BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Aguettant System, and Cysview. The company was founded on April 28, 1947 and is headquartered in Toronto, Canada.
The company’s shares closed on Wednesday at C$8.11.